Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men

J Eur Acad Dermatol Venereol. 2021 Jan;35(1):e13-e15. doi: 10.1111/jdv.16953. Epub 2020 Oct 21.

Abstract

The COVID‐19 pandemic has disproportionally affected men.1 Men infected with SARS‐CoV‐2 are more than twice as likely to be admitted to the intensive care unit (ICU).2 This disparity in ICU admissions suggests the important role of androgens in COVID‐19 severity.3 Previously, we reported that among 122 men hospitalized due to COVID‐19, 79% were diagnosed with androgenetic alopecia (AGA),4 which is commonly treated with anti‐androgens. Anti‐androgens commonly used in the treatment of AGA such as finasteride, dutasteride, spironolactone, and bicalutamide could improve outcomes among men infected by SARS‐CoV‐2.

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / therapeutic use*
  • COVID-19*
  • Dutasteride / therapeutic use
  • Finasteride / therapeutic use
  • Humans
  • Intensive Care Units
  • Male
  • Middle Aged
  • Observational Studies as Topic
  • Patient Admission*
  • Prospective Studies
  • SARS-CoV-2
  • Spironolactone / therapeutic use

Substances

  • Androgen Antagonists
  • Spironolactone
  • Finasteride
  • Dutasteride